Showing 121 - 140 results of 15,683 for search '(((( i larvae increases ) OR ( arl values decrease ))) OR ( ((b large) OR (a large)) decrease ))', query time: 0.93s Refine Results
  1. 121
  2. 122

    A super-SILAC based proteomics analysis of diffuse large B-cell lymphoma-NOS patient samples to identify new proteins that discriminate GCB and non-GCB lymphomas by L. E. van der Meeren (7490675)

    Published 2019
    “…<div><p>Diffuse large B-cell lymphoma—not otherwise specified (DLBCL-NOS) is a large and heterogeneous subgroup of non-Hodgkin lymphoma. …”
  3. 123
  4. 124

    Table_2_Tumor Immune Microenvironment Components and Checkpoint Molecules in Anaplastic Variant of Diffuse Large B-Cell Lymphoma.pdf by Tianqi Xu (9574329)

    Published 2021
    “…Background<p>Anaplastic diffuse large B-cell lymphoma(A-DLBCL) is a rare morphological subtype characterized by the presence of polygonal, bizarre-shaped tumor cells. …”
  5. 125

    Table_1_Tumor Immune Microenvironment Components and Checkpoint Molecules in Anaplastic Variant of Diffuse Large B-Cell Lymphoma.pdf by Tianqi Xu (9574329)

    Published 2021
    “…Background<p>Anaplastic diffuse large B-cell lymphoma(A-DLBCL) is a rare morphological subtype characterized by the presence of polygonal, bizarre-shaped tumor cells. …”
  6. 126

    Prognostic value of lactate dehydrogenase, serum albumin and the lactate dehydrogenase/albumin ratio in patients with diffuse large B-cell lymphoma by Wenke Wu (17665962)

    Published 2023
    “…<p>To investigate the prognostic value of lactate dehydrogenase (LDH), serum albumin (ALB) and the lactate dehydrogenase/albumin ratio (LAR) in diffuse large B-cell lymphoma (DLBCL) before primary treatment.…”
  7. 127
  8. 128
  9. 129
  10. 130
  11. 131
  12. 132
  13. 133
  14. 134
  15. 135
  16. 136
  17. 137
  18. 138

    DataSheet_1_A nationwide analysis of the treatment patterns, survival, and medical costs in Korean patients with relapsed or refractory diffuse large B-cell lymphoma.docx by Jeong-Yeon Cho (11787386)

    Published 2024
    “…Background<p>Approximately one-third of patients with diffuse large B-cell lymphoma (DLBCL) are refractory to treatment or experience relapse after initial therapy. …”
  19. 139
  20. 140